Cannabis Science (OTCMKTS: CBIS) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for Cannabis Science and Miragen Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cannabis Science 0 0 0 0 N/A
Miragen Therapeutics 0 0 3 0 3.00

Miragen Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 210.48%. Given Miragen Therapeutics’ higher probable upside, analysts plainly believe Miragen Therapeutics is more favorable than Cannabis Science.

Risk & Volatility

Cannabis Science has a beta of -3.62, meaning that its share price is 462% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Profitability

This table compares Cannabis Science and Miragen Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cannabis Science -953,196.00% N/A -380.46%
Miragen Therapeutics -720.38% -80.31% -64.59%

Valuation & Earnings

This table compares Cannabis Science and Miragen Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cannabis Science N/A N/A N/A N/A N/A
Miragen Therapeutics $3.34 million 51.63 -$12.67 million ($8.93) -0.87

Cannabis Science has higher earnings, but lower revenue than Miragen Therapeutics.

Insider & Institutional Ownership

22.6% of Miragen Therapeutics shares are owned by institutional investors. 44.4% of Miragen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Miragen Therapeutics beats Cannabis Science on 8 of the 9 factors compared between the two stocks.

Cannabis Science Company Profile

Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Miragen Therapeutics Company Profile

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive News & Ratings for Cannabis Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannabis Science Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.